Cancer vaccines (Part 2 of 2)

P. A. Hallin; V. R. Adams

doi:10.1016/s1086-5802(16)30268-6

Cancer vaccines (Part 2 of 2)

Research output: Contribution to journal › Short survey › peer-review

Original language	English
Pages (from-to)	706-709
Number of pages	4
Journal	Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Volume	37
Issue number	6
DOIs	https://doi.org/10.1016/s1086-5802(16)30268-6
State	Published - 1997

Bibliographical note

Funding Information:
is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Funding

is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Funders	Funder number
Ameri can Pharmaceutical Asso ciation

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1086-5802(16)30268-6

Cite this

@article{135f2a3451e0447b8475040080b702ff,

title = "Cancer vaccines (Part 2 of 2)",

author = "Hallin, \{P. A.\} and Adams, \{V. R.\}",

note = "Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.",

year = "1997",

doi = "10.1016/s1086-5802(16)30268-6",

language = "English",

volume = "37",

pages = "706--709",

number = "6",

}

TY - JOUR

T1 - Cancer vaccines (Part 2 of 2)

AU - Hallin, P. A.

AU - Adams, V. R.

N1 - Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

PY - 1997

Y1 - 1997

UR - https://www.scopus.com/pages/publications/0031264050

UR - https://www.scopus.com/inward/citedby.url?scp=0031264050&partnerID=8YFLogxK

U2 - 10.1016/s1086-5802(16)30268-6

DO - 10.1016/s1086-5802(16)30268-6

M3 - Short survey

C2 - 9425801

AN - SCOPUS:0031264050

SN - 1086-5802

VL - 37

SP - 706

EP - 709

JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

IS - 6

ER -

Cancer vaccines (Part 2 of 2)

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this